Dinovate Biotech

Dinovate Biotech is a biopharmaceutical company specializing in the discovery and development of innovative protein and antibody therapeutics using artificial intelligence. The company utilizes its proprietary "Dino-Platform" to design de novo proteins and optimize complex molecules, such as next-generation cytokines and bispecific antibodies, targeting traditionally "undruggable" biological spaces. Its lead pipeline programs, including DIN-01 and DIN-02, are engineered cytokine prodrugs designed to maximize anti-tumor efficacy while significantly reducing systemic toxicity. Headquartered in Beijing, China, Dinovate was founded by industry veterans with extensive experience at global pharmaceutical firms like Amgen and is supported by prominent venture capital investors including Matrix Partners China and Gaorong Capital.